Comparison of long-term oncologic outcomes of stage III colorectal cancer following laparoscopic versus open surgery.
- Author:
Jeong Heum BAEK
1
;
Gil Jae LEE
;
Won Suk LEE
Author Information
- Publication Type:Original Article
- Keywords: Colorectal neoplasms; Laparoscopy; Stage III; Disease-free survival; Survival
- MeSH: Colon; Colonic Neoplasms; Colorectal Neoplasms*; Disease-Free Survival; Follow-Up Studies; Humans; Laparoscopy; Rectal Neoplasms
- From:Annals of Surgical Treatment and Research 2015;88(1):8-14
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The oncologic outcomes after performing laparoscopic surgery (LS) compared to open surgery (OS) are still under debate and a concern when treating patients with colon cancer. The aim of this study was to compare the long-term oncologic outcomes of LS and OS as treatment for stage III colorectal cancer patients. METHODS: From January 2001 to December 2007, 230 patients with stage III colorectal cancer who had undergone LS or OS in this single center were assessed. Data were analyzed according to intention-to-treat. The primary endpoints were disease-free survival and overall survival. RESULTS: A total of 230 patients were entered into the study (114 patients had colon cancer-33 underwent LS and 81 underwent OS; 116 patients had rectal cancer-44 underwent LS and 72 underwent OS). The median follow-up periods for the colon and rectal cancer groups were 54 and 53 months, respectively. The overall conversion rate was 12.1% (n = 4) for colon cancer, and 4.5% (n = 2) for rectal cancer. Disease-free 5-year survival of colon cancer was 84.3% and 90% in LS group (LG) and OS group (OG), respectively, and that of rectal cancer was 83% and 74.6%, respectively (P > 0.05). Overall 5-year survival for colon cancer was 72.2% and 71.3% for LG and OG, respectively, and that for rectal cancer was 67.6% and 59.2%, respectively (P > 0.05). CONCLUSION: The long-term analyses for oncologic aspects of our study may confirm the safety of LS compared to OS in stage III colorectal cancer patients.
